![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Miltenyi Biotec, GSK Enter Cell and Gene Therapy Development Partnership
Miltenyi Biotec, GSK Enter Cell and Gene Therapy Development Partnership
![correct_handshake.gif](https://www.fdanews.com/ext/resources/test/Device_Images/handshake.gif?t=1576815772&width=430)
March 22, 2016
GlaxoSmithKline and Miltenyi Biotec are partnering to develop a cell and gene therapy platform, the companies announced last week.
Their collaboration will focus on discovering new chimeric antigen-receptor T-cell based therapeutics, with an eye toward optimizing manufacture and delivery to support the development of novel therapies in oncology and rare diseases.
Upcoming Events
-
21Oct